Skip to content

Study · Not a test of the peptide alone · 2022

4 results

Electrospun nanofibers containing chitosan-stabilized bovine serum albumin nanoparticles for bone regeneration.

Lin P, Zhang W, Chen D, Yang Y, Sun T, Chen H, Zhang J

Colloids and surfaces. B, Biointerfaces30 Jun 2022Cited by 19 (Europe PMC)

PMID35803032 (opens in a new tab)DOI10.1016/j.colsurfb.2022.112680 (opens in a new tab)PepBankPUB-35803032
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Efficacy outcome

    Dual-drug scaffolds containing abaloparatide and aspirin enhanced osteoblast proliferation.

    In plain wordsIn cells, scaffolds containing abaloparatide and aspirin increased osteoblast multiplication.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoblast proliferation
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The dual-drug-loaded nanofiber scaffolds enhanced the proliferation and osteogenic differentiation of osteoblasts.
    1 context sentence
    Summary · context
    In the present study, we fabricated a nanofiber scaffold containing chitosan-stabilized bovine serum albumin (BSA) nanoparticles for the delivery of abaloparatide and aspirin (ASA).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Efficacy outcome

    Dual-drug scaffolds containing abaloparatide and aspirin enhanced osteogenic differentiation of osteoblasts.

    In plain wordsIn cells, scaffolds containing abaloparatide and aspirin increased bone-forming differentiation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteogenic differentiation
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The dual-drug-loaded nanofiber scaffolds enhanced the proliferation and osteogenic differentiation of osteoblasts.
    1 context sentence
    Summary · context
    In the present study, we fabricated a nanofiber scaffold containing chitosan-stabilized bovine serum albumin (BSA) nanoparticles for the delivery of abaloparatide and aspirin (ASA).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 03LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other

    The dual-drug scaffolds successfully encapsulated abaloparatide and aspirin.

    In plain wordsIn lab tests, the scaffolds successfully held abaloparatide and aspirin.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableDrug encapsulation
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The results showed that the drugs were successfully encapsulated in the scaffolds.
    1 context sentence
    Summary · context
    In the present study, we fabricated a nanofiber scaffold containing chitosan-stabilized bovine serum albumin (BSA) nanoparticles for the delivery of abaloparatide and aspirin (ASA).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other

    The scaffolds released abaloparatide for more than 30 days.

    In plain wordsIn lab tests, the scaffolds released abaloparatide for more than 30 days.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableAbaloparatide release
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Release duration
    > 30 days
    abaloparatide from scaffolds

    Source sentences

    Summary
    Most of the ASA was released within seven days, whereas abaloparatide was released for more than 30 days.
    1 context sentence
    Summary · context
    In the present study, we fabricated a nanofiber scaffold containing chitosan-stabilized bovine serum albumin (BSA) nanoparticles for the delivery of abaloparatide and aspirin (ASA).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.